Apolipoprotein A1 and B.
This article reviews the evidence showing that apolipoprotein (apo) B and A-1 are superior to the conventional cholesterol indices as analytes in laboratory practice, indices of the lipoprotein-related risk for vascular disease, and measures of the adequacy of low-density lipoprotein-lowering therapy.
Sniderman
Allan D
AD
Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7.22, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada. allansniderman@hotmail.com
Marcovina
Santica M
SM
D016632:Apolipoprotein A-I / Q000097:blood* / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood* / Q000378:metabolism; D050197:Atherosclerosis / Q000188:drug therapy / Q000209:etiology; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006951:Hyperlipoproteinemias / Q000175:diagnosis / Q000188:drug therapy; D018570:Risk Assessment
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors